- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Novavax Inc (NVAX)
Track today's live Novavax (NVAX) share price, performance and key data on this page with our current NASDAQ:NVAX stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Novavax share price on the NASDAQ exchange. Use the dropdown to switch exchange for the NVAX share price, head to our technical summary section, which provides analysis on Novavax share price buy/sell indicators using real-time data (or discuss the Novavax (NVAX) stock price today with other investors in the Novavax NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:NVAX share price (ISIN: US6700024010) to enhance your trading decisions with our free investment tools and resources.
What Is the Novavax Inc Share Price Today?
The Novavax share price today is 9.260.
What Is the Stock Symbol for Novavax Inc
The stock symbol (or 'ticker') for Novavax Inc is "NVAX."
What Stock Exchange Does Novavax Inc Trade On?
Novavax Inc is listed and trades on the NASDAQ stock exchange.
Is Novavax Inc a Good Stock to Buy?
Determining whether Novavax (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:NVAX share price (ISIN: US6700024010) to enhance your trading decisions with our free investment tools and resources.
What Is the Novavax Inc Share Price Today?
The Novavax share price today is 9.260.
What Is the Stock Symbol for Novavax Inc
The stock symbol (or 'ticker') for Novavax Inc is "NVAX."
What Stock Exchange Does Novavax Inc Trade On?
Novavax Inc is listed and trades on the NASDAQ stock exchange.
Is Novavax Inc a Good Stock to Buy?
Determining whether Novavax (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.890
9.340
52 wk Range
6.200
11.970
NVAX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
8.8909.340
52 wk Range
6.20011.970
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NVAX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
14.002
Upside
+51.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
5 Buy
1 Hold
3 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 14.002
(+51.21% Upside)
Novavax Inc Earnings Call Summary for Q2/2026
- Novavax posted Q2 adjusted EPS of -$0.32, beating estimates of -$0.40, with revenue of $57M topping forecasts of $52.06M despite sharp YoY decline.
- Company raised 2026 revenue guidance to $235M-$275M (midpoint $255M) from prior $250M midpoint, expecting Q4 to deliver most remaining revenue.
- Operating expenses cut over 80% from peak levels; management targets non-GAAP profitability by 2028 while pivoting to partnership-focused model.
- Cash and receivables totaled $743M at quarter-end; expects $75M Sanofi milestone mid-2027 and potential $125M Phase III milestone for COVID-flu combo.
- Product sales rose 76% YoY to $19M driven by Matrix-M adjuvant demand; Sanofi-related revenue contributed $36M from R&D reimbursements and amortization.
Last Updated: 06/08/2026, 15:02
Read Full TranscriptEarnings
Latest Release
06/08/2026
EPS / Forecast
-0.32 / -0.40
Revenue / Forecast
57M / 52.06M
Compare NVAX to Peers and Sector
Metrics to compare | NVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNVAXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −6.2x | −6.6x | −0.4x | |
PEG Ratio | 0.04 | 0.04 | 0.00 | |
Price/Book | −8.0x | 1.3x | 2.6x | |
Price / LTM Sales | 3.7x | 8.4x | 3.1x | |
Upside (Analyst Target) | 73.0% | 262.3% | 48.1% | |
Fair Value Upside | Unlock | 1.7% | 6.3% | Unlock |
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Novavax (NASDAQ: NVAX) Share Price Today?
The Novavax stock price today is 9.260 USD.
What Stock Exchange Does Novavax (NVAX) Trade On?
Novavax is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Novavax?
The stock symbol (also called a 'ticker') for Novavax is "NVAX."
What Is the Current Novavax Market Capitalisation?
As of today, Novavax (NASDAQ: NVAX) market cap is 1.530B USD.
What Is Novavax's (NVAX) Earnings Per Share (TTM)?
The Novavax EPS is currently -1.518 (Trailing Twelve Months).
When Is the Next Novavax Earnings Date?
Novavax's next earnings report will be released on 05/11/2026.
Is NVAX a Buy or Sell From a Technical Analyst Perspective?
Based on today's Novavax moving averages and other technical indicators, the daily buy/sell signal for NVAX stock is Strong Buy.
How Many Times Has Novavax Stock Split?
Novavax has split 1 times. (See the NVAX stock split history page for full effective split date and price information.)
How Many Employees Does Novavax Have?
Novavax has 749 employees, based on their latest Companies House report.
What is the current trading status of Novavax (NASDAQ: NVAX)?
As of 30/08/2026, Novavax (NVAX) is trading at a share price of 9.260 USD, with a previous close of 9.050 USD. The stock has fluctuated within a day range of 8.890 USD to 9.340 USD, while its 52-week range spans from 6.200 USD to 11.970 USD.
What Is Novavax (NVAX) Price Target According to Analysts?
The average 12-month price target for Novavax is 14.002 USD, with a high estimate of 25 USD and a low estimate of 7 USD. 5 analysts recommend buying the stock, while 3 suggest selling, leading to an overall rating of Buy. The stock has an +51.21% Upside potential.
What Is the NVAX Premarket Price?
NVAX's last pre-market stock price is 9.200 USD. The pre-market share volume is 85,070.000, and the stock has decreased by 0.150, or 1.660%.
What Is the NVAX After Hours Price?
NVAX's last after hours stock price is 9.270 USD, the stock has decreased by 0.010, or 0.110%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.